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The fibrinolytic system is activated concurrently with coagulation, it regulates haemostasis and prevents 3 
thrombosis by restricting clot formation to the area of vascular injury and dismantling the clot as healing 4 
occurs. Dysregulation of the fibrinolytic system resulting in hyperfibrinolysis may manifest as clinically 5 
significant haemorrhage. Hyperfibrinolysis occurs in both cats and dogs secondary to a variety of 6 
congenital and acquired disorders. It has been described in cats and dogs with conditions commonly 7 
encountered in primary care practice such as trauma, cavitary effusions, liver disease and Angiostrongylus 8 
vasorum. In addition, delayed haemorrhage reported in Greyhounds following trauma and routine surgical 9 
procedures has been attributed to a hyperfibrinolytic disorder that has yet to be characterised.  10 
 11 
Diagnosis of hyperfibrinolysis is challenging, and until recently has relied on techniques that are not 12 
readily available outside of a referral hospital setting.  With the recent development of point of care 13 
viscoelastic techniques, assessment of fibrinolysis is now possible within primary care practice. This will 14 
provide veterinary surgeons with the opportunity to target haemorrhage due to hyperfibrinolysis with 15 
antifibrinolytic drugs and reduce associated morbidity and mortality.  The fibrinolytic system and the 16 
conditions associated with increased fibrinolytic activity in cats and dogs are the focus of this review 17 
article.  In addition, laboratory and point of care techniques for assessing hyperfibrinolysis and 18 
antifibrinolytic treatment for patients with haemorrhage will be reviewed.  19 
 20 
The Fibrinolytic System 21 
Primary haemostasis is initiated following vascular injury and results in the formation of a haemostatic 22 
plug consisting of platelets, von Willebrand factor and exposed subendothelial collagen. This haemostatic 23 
plug provides a surface for secondary haemostasis, activation of coagulation factors, thrombin generation 24 
and fibrin formation (Smith, 2009). Fibrinolysis is activated concurrently with coagulation and restricts 25 
clot formation to the area of vascular injury via plasmin mediated lysis of fibrinogen and fibrin, in order 26 
to preserve vascular patency the fibrinolytic system dismantles the clot as healing occurs (Ekert and 27 
Muntz, 1972). Under physiological conditions fibrinolysis is controlled by co-factors, receptors and 28 
 3 
inhibitors, which regulate haemostasis and prevent thrombosis (Figure 1). Dysregulation of the 29 
fibrinolytic system results in hypofibrinolysis or hyperfibrinolysis, which may manifest clinically as 30 
thrombosis or haemorrhage respectively. Investigation of the fibrinolytic system should be considered in 31 
patients with haemorrhage when surgical haemostasis has been achieved and investigations do not reveal 32 
a primary or secondary haemostatic disorder.  33 
 34 
Activation of fibrinolysis 35 
Plasmin is the primary fibrinolytic protease, it is converted from circulating inactive plasminogen by tissue 36 
plasminogen activator (tPA) and urokinase plasminogen activator (uPa). Direct injury or stimulation of 37 
vascular endothelial cells results in the release of tPA and factor XII activation following contact with 38 
negatively charged surfaces (Kooistra et al., 1994; Renné, 2012). Factor XIIa complexes with kininogen 39 
and pre-kallikrein to form bradykinin which potently induces more tPA release from endothelial cells 40 
(Brown et al., 1999). Plasmin cleaves fibrinogen and fibrin, resulting in the exposure of fibrin carboxyl 41 
terminal lysine residues which further enhance fibrinolysis by acting as binding sites for tPA and 42 
plasminogen (Ekert & Muntz, 1972; Cesarman-Maus & Hajjar, 2005). Lysis of fibrin results in the 43 
formation of soluble fibrin degradation products (FDP’s) including D-dimers.  44 
 45 
Inhibition and attenuation of fibrinolysis 46 
The three main inhibitors of fibrinolysis are plasminogen activator inhibitor-1 (PAI-1), alpha-2-47 
antiplasmin and thrombin activatable fibrinolysis inhibitor (TAFI), which are primarily produced by the 48 
liver (Saito et al., 1982; Eaton et al., 1991; Knittel et al., 1996). PAI-1 is the main inhibitor of tPA and 49 
uPA and therefore the most significant inhibitor of fibrinolysis (Loskutoff et al., 1989; van Meijer & 50 
Pannekoek, 1995). Alpha-2 antiplasmin inhibits fibrinolysis by forming a complex with active plasmin to 51 
neutralise its action and also by preventing absorption of plasminogen onto the fibrin clot. Alpha-2 52 
antiplasmin also crosslinks fibrin and factor XIIIa which strengthens the fibrin clot and enhances its 53 
resistance to plasmin (Carpenter & Mathew, 2008). TAFI is activated by thrombin in a reaction that is 54 
catalysed by thrombomodulin (Bajzar et al., 1996; Bouma & Meijers, 2004). TAFI is a potent down-55 
regulator of fibrinolysis; by removing carboxyl-terminal lysine groups from fibrin strands it prevents the 56 
 4 
binding of plasminogen and tPA to the thrombus. TAFI decreases plasminogen activation, attenuates 57 
positive feedback from plasmin and at high concentrations also directly inhibits plasmin (Mosnier & 58 
Bouma, 2006; Foley et al., 2013). The anticoagulant, pro-fibrinolytic enzyme activated protein C 59 
neutralises PAI-1 and attenuates the production of TAFI (Sakata et al., 1986; Bajzar et al., 1996).  60 
(Figure 1) 61 
 62 
Hyperfibrinolytic Disorders 63 
Hyperfibrinolytic disorders result in premature clot lysis and haemorrhage, which may be further 64 
exacerbated by the development of a consumptive coagulopathy if dysregulation of fibrinolysis persists 65 
(Hunt, 1996; Rizoli et al., 2011; Sigrist et al., 2018). In human and veterinary medicine, haemorrhage due 66 
to hyperfibrinolysis has been associated with both congenital and acquired disorders and can be classified 67 
as primary or secondary. Primary hyperfibrinolysis occurs due to quantitative or qualitative abnormalities 68 
of the proteins involved in the regulation of the fibrinolytic pathway (Kolev and Longstaff, 2016). 69 
Secondary hyperfibrinolysis describes hyperactivity of a normal fibrinolytic pathway, typically provoked 70 
by abnormal coagulation, or hyperfibrinolysis due to increased susceptibility of fibrin to lysis (Kolev and 71 
Longstaff, 2016). Although this method of classification requires further refinement, it clarifies the 72 
underlying pathophysiology of hyperfibrinolysis, contextualising its role within the systemic status of the 73 
patient, and may be helpful in guiding therapeutic interventions.  74 
 75 
Laboratory Assessment of Fibrinolysis 76 
Methods to measure the individual components of the fibrinolytic pathway are not readily available in 77 
practice, cost prohibitive and frequently lack validation for veterinary species. Elevated FDP and D-dimer 78 
concentrations indicate increased fibrinolytic activity, however they lack specificity and viscoelastic 79 
techniques are currently considered superior for assessing fibrinolysis (Spiel et al., 2006; Schöchl et al., 80 
2009; Longstaff, 2018). It is important to note that even viscoelastic techniques are imperfect and may 81 
either fail to detect hyperfibrinolysis or conversely report hyperfibrinolysis in apparently healthy patients 82 
(Raza et al., 2013; Sigrist et al., 2018).  83 
 84 
 5 
Fibrin/fibrinogen degradation products & D-dimers   85 
FDPs are produced following plasmin-mediated lysis of fibrinogen and/or fibrin, thus elevated FDP’s 86 
indicate increased fibrinolytic activity (Bick., 1982). Fibrinogen is present in the circulation regardless of 87 
whether or not clot formation has occurred, as such the presence of FDPs is not a specific marker of clot 88 
formation and lysis. D-dimers are a specific form of FDP produced following plasmin-mediated lysis of 89 
cross-linked fibrin, with elevations indicating that activation of coagulation and fibrinolysis has occurred 90 
(Elms et al., 1983; Greenberg et al., 1985). Point of care kits to assess FDP and D-dimer concentrations 91 
are available and have been evaluated for their utility in dogs and cats (Stokol et al., 1999; Griffin et al., 92 
2003; Brazzell & Borjesson, 2007; Dewhurst et al., 2008; Bauer & Moritz, 2009; Tholen et al., 2009). 93 
Discordant FDP and D-dimer results, i.e. elevated FDPs alongside normal D-dimer concentration, are 94 
possible and have been attributed to primary hyperfibrinolysis and laboratory technique (Sato et al., 1995; 95 
Song et al., 1999; Zoia et al., 2017, 2018).  96 
 97 
Elevated FDPs and D-dimers are supportive of, but not specific to, hyperfibrinolysis. Mildly elevated 98 
FDPs/D-dimers are documented during normal post-operative healing in dogs (Sobiech et al., 2011; 99 
Moldal et al., 2012; Shipov et al., 2018). Increased FDP’s/D-dimers are also associated with pathological 100 
processes such as disseminated intravascular coagulation (DIC) or thromboembolic disease in which a 101 
regulated hyperfibrinolysis represents an initial protective mechanism (Stokol et al., 1999; Nelson & 102 
Andreasen, 2003; Stokol, 2003; Machida et al., 2010). Due to this lack of specificity FDPs/D-dimers 103 
should not be used to identify patients with hyperfibrinolysis who would benefit from antifibrinolytic 104 
therapy. Antifibrinolytic drugs are contraindicated in thromboembolic disease and rarely recommended in 105 
people with DIC, therefore the administration of antifibrinolytic drugs to patients based on elevated 106 
FDP’s/D-dimers has the potential to cause harm. (Wada et al., 2010).  107 
 108 
Viscoelastic techniques 109 
Viscoelastic tests provide a global assessment of the coagulation system by detecting the change in blood 110 
viscosity as the different coagulation phases occur. Rotational thromboelastometry (ROTEM) and 111 
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thromboelastography (TEG) can be used to diagnose hypocoagulability, hypercoagulability, enhanced and 112 
reduced fibrinolysis (Kol and Borjesson, 2010; McMichael and Smith, 2011).  113 
 114 
Samples for TEG and ROTEM are collected into 3.2% buffered sodium citrate and standardised 115 
sampling protocols advised (Flatland et al., 2014). Before testing, samples are recalcified and in-vitro 116 
coagulation is accelerated and preanalytical errors are reduced with the use of contact activators (Wiinberg 117 
et al., 2005, 2007; Bauer & Moritz, 2009). TEG activators used for the assessment of fibrinolysis include 118 
kaolin and kaolin combined with tissue factor (Rapid TEG). Tissue factor is utilised to activate the 119 
extrinsic pathway when assessing fibrinolysis using ROTEM. Results obtained using different activators 120 
are not directly comparable (Wiinberg et al., 2005, 2007; Bauer & Moritz, 2009). 121 
 122 
Analysis is performed following a standardised 30 minute delay and within 2 hours of collection (Goggs 123 
et al., 2014).  Whole blood is placed in a cup and warmed to 37oC, a pin attached to a torsion wire is 124 
suspended within the cup. The torsion wire is connected to a mechanical-electrical transducer. TEG 125 
operates by moving the cup around the stationary pin in a gentle arc. ROTEM has an immobile cup and 126 
instead the pin slowly oscillates. Coagulation results in the formation of fibrin strands between the cup 127 
and the pin. Movement of the cup (TEG) or pin (ROTEM) creates different degrees of torsion according 128 
to blood viscosity, and as fibrinolysis occurs torsional forces are reduced. Changes in torsional forces on 129 
the pin are converted into electrical signals. Graphical and numerical information is created from 130 
electrical signals and presented as the thromboelastogram (ROTEM) or thromboelastograph (TEG). It is 131 
important to note that although thromboelastogram tracings for TEG and ROTEM appear similar they 132 
are not directly comparable. 133 
 134 
Fibrinolysis is reported as the percentage reduction in clot strength at 30 and 60 minutes after maximal 135 
clot strength is achieved (TEG) and percentage lysis at 30 and 60 mins following initiation of clotting 136 
(ROTEM). In vitro fibrinolysis proceeds slowly due to an imbalance of anti-fibrinolytic and pro-137 
fibrinolytic factors. Whole blood samples contain anti-fibrinolytic factors, such as alpha-2 antiplasmin, 138 
which circulate in plasma (Sabovic et al., 1989). Consequently in vitro fibrinolysis may not be detectable 139 
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within the testing timeframe or before sample dehydration occurs. Modification of TEG assays with 140 
recombinant tissue plasminogen activator (tPA) has been shown to accurately reflect the fibrinolytic 141 
potential of whole blood and aid detection of fibrinolytic dysfunction (Figure 2) (Kupesiz et al., 2010; 142 
Spodsberg et al., 2013; Fletcher et al., 2016; Yoo et al., 2016). The use of tPA in ROTEM to diagnose 143 
fibrinolytic dysfunction is not reported in the veterinary literature but is reported in people (Kuiper et al., 144 
2016).  145 
(Figure 2) 146 
ROTEM offers four standard tracings, INTEM, EXTEM, APTEM, FIBTEM, which are interpreted 147 
together. EXTEM and APTEM are utilised for the detection of fibrinolytic disorders and contain tissue 148 
factor (TF) which activates the extrinsic pathway (Srivastava and Kelleher, 2013). Aprotinin is added to 149 
APTEM to inhibit fibrinolysis, increased clot lysis on EXTEM combined with a normal APTEM tracing 150 
indicates hyperfibrinolysis (Marly-Voquer et al., 2017).  151 
 152 
Viscoelastometry is available in specialist hospitals, but currently is not routinely utilised in primary care 153 
practice.  Portable handheld viscoelastic analysers are now available and have been recently validated in 154 
both canine and feline patients (Buriko & Silverstein, 2018; Jandrey et al., 2018). In the future, as our 155 
understanding of the utility and application of viscoelastic techniques develops alongside advances in 156 
technology, it is likely that viscoelastic techniques will be integrated into primary care practice. Practices 157 
utilising point of care viscoelastic devices will need to use established veterinary clinical pathology 158 
guidelines to determine reference intervals (Goggs et al., 2014).  159 
 160 
Congenital Hyperfibrinolysis 161 
Congenital hyperfibrinolysis occurs due to increased clot fragility and susceptibility to fibrinolysis 162 
(resulting from quantitative or qualitative factor issues), and/or a deficiency of fibrinolytic inhibitors. In 163 
people congenital hyperfibrinolysis is reported due to alpha-2 antiplasmin deficiency, PAI-1 deficiency, 164 
haemophilia, FXIII deficiency and dysfibrinogenaemia (Anwar & Miloszewski, 1999; Maino et al., 2008; 165 
Mehta & Shapiro, 2008; Kolev & Longstaff, 2016). Haemophilia A and B occur in both cats and dogs 166 
(Cotter et al., 1978; Brooks, 1999; Barr & McMichael, 2012). Reports of congenital FXIII deficiency and 167 
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fibrinogen disorders within the veterinary literature are extremely rare, alpha-2 antiplasmin and PAI-1 168 
deficiency have not been reported (Kammermann et al., 1971; Cotter et al., 1978; Wilkerson et al., 2005; 169 
Chambers, 2013; Kong et al., 2014; Jolivet et al., 2017). Deficiency of the anti-fibrinolytic serpins alpha-2 170 
antiplasmin and PAI-1 results in disinhibition of the fibrinolytic system and primary hyperfibrinolysis 171 
(Kolev & Longstaff, 2016; Franchini & Mannucci, 2018). Haemophilia, FXIII deficiency and 172 
dysfibrinogenaemia are coagulopathies which stimulate upregulation of the fibrinolytic system and 173 
secondary hyperfibrinolysis (Kolev & Longstaff, 2016; Franchini & Mannucci, 2018). A hyperfibrinolytic 174 
profile has been recognised in the Greyhound breed which likely represents an inherited coagulopathy 175 





Haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are sex linked inherited 181 
coagulopathies reported to occur in both dogs and cats (Littlewood, 1989; Barr & McMichael, 2012). 182 
Haemophilia C, due to factor XI deficiency, has also been reported in dogs and cats (Dodds & Kull, 183 
1971; Knowler et al., 1994; Troxel et al., 2002). The critical role of factors VIII and FIX in coagulation is 184 
best illustrated by the cell based model of coagulation (Smith, 2009). In people with haemophilia 185 
haemorrhage occurs due to both defective coagulation and up-regulated fibrinolysis (Broze & Higuchi, 186 
1996; Mosnier et al., 2001; Foley & Nesheim, 2009). A more intensely haemorrhagic phenotype has been 187 
reported in human haemophiliacs with hyperfibrinolysis (Grünewald et al., 2002).  188 
 189 
Impaired thrombin production affects fibrin structure and cross-linking, impairs platelet accumulation 190 
and decreases TAFI activation ( Wolberg & Campbell, 2008; Brummel-Ziedins et al., 2009; Foley & 191 
Nesheim, 2009). Haemophiliacs with impaired thrombin production form loose fibrin clots with high 192 
permeability constants that are susceptible to lysis (Bettigole et al., 1964; Sixma & Wester, 1977; Fraser et 193 
al., 2011). Thrombin activates FXIII which crosslinks fibrin monomers to stabilise clots, so decreased 194 
FXIIIa results in the formation of fragile clots susceptible to lysis (Lorand et al., 1981; Muszbek et al., 195 
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1999). Finally, thrombin is required for activation of TAFI and insufficient TAFIa is associated with 196 
premature clot lysis (Broze & Higuchi, 1996; Foley & Nesheim, 2009). Haemophiliac dogs treated with 197 
low dose soluble thrombomodulin to increase TAFIa produced clots that were more resistant to 198 
fibrinolysis (Foley et al., 2012).  199 
 200 
The pathophysiology of haemophilia A and B in people and dogs is similar, to the extent that dogs are 201 
used in research as a disease model to assess the efficacy of therapeutic interventions (Nichols et al., 202 
2010). Hyperfibrinolysis has not been reported in dogs and cats with haemophilia and further studies are 203 
required to investigate the role of hyperfibrinolysis in cats and dogs with haemorrhage due to 204 
haemophilia. The use of viscoelastic techniques to assess global coagulation is reported in haemophiliac 205 
dogs (Othman et al., 2009; Aroch et al., 2015). However, in the study by Othman et al (2009) TEG 206 
tracings were only recorded until maximum amplitude was reached and hyperfibrinolysis was not 207 
assessed. The single case report by Aroch et al (2015) did not document hyperfibrinolysis on ROTEM in 208 
a dog with Haemophilia A.  209 
 210 
Recombinant factor VIII and IX replacement therapy is used for prophylaxis and treatment in people 211 
with haemophilia. Studies have demonstrated a reduction of spontaneous bleeding episodes in 212 
haemophiliac dogs treated prophylactically with both plasma derived, and recombinant human, factors 213 
VIII and IX, however specific factor replacement therapy is not routinely available for veterinary patients 214 
(Brinkhous et al., 1985, 1996, 2002; Russell et al., 2003) . The mainstay of treatment in cats and dogs with 215 
haemophilia is blood product administration, during bleeding episodes or prior to planned surgical 216 
procedures, in the form of cryoprecipitate (for haemophilia A), fresh frozen plasma, whole blood or 217 
packed red blood cells (Aslanian et al., 2014). In the absence of effective haemorrhage prophylaxis 218 
repeated blood product administration represents a considerable financial commitment for clients. 219 
Antifibrinolytic therapy also forms part of haemorrhage prophylaxis and treatment in people with 220 
haemophilia ( Rizza, 1980; Ghosh, 2004; Hvas et al., 2007). Currently evidence does not exist to support 221 
the use of antifibrinolytic therapy in veterinary patients with haemophilia. However, antifibrinolytic 222 
therapy is unlikely to cause harm and could be considered for haemorrhage prophylaxis and treatment in 223 
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cats and dogs with severe haemophilia prior to considering euthanasia (Aroch et al., 2015; Kelmer et al., 224 
2015).  225 
  226 
Fibrinogen Disorders 227 
Fibrinogen is cleaved to fibrin by thrombin and then fibrin monomers are polymerised to form the 228 
network of fibres essential for the foundation of a stable clot (Lord, 2011). Acquired quantitative and 229 
qualitative fibrinogen disorders occur rarely in people and are challenging to diagnose (Al-Mondhiry & 230 
Ehmann, 1994; de Moerloose et al., 2013). Fibrinogen disorders are typically asymptomatic with 231 
haemorrhage occurring following trauma or surgery (Moen & Lord 2006). Afibrinogenemia has been 232 
reported in a Bernese Mountain Dog, a Chihuahua and a Bichon Frise, while hypofibrinogenaemia has 233 
been reported in a German Short Haired Pointer (Kammermann et al., 1971; Wilkerson et al., 2005; 234 
Chambers, 2013). The treatment of choice for veterinary patients with haemorrhage secondary to 235 
fibrinogen disorders is cryoprecipitate or fresh frozen plasma to replenish fibrinogen. Thromboembolic 236 
complications are reported in people with congenital fibrinogen disorders, although the underlying 237 
pathophysiology is incompletely understood (Korte et al., 2017). As such the use of antifibrinolytic agents 238 
in cats and dogs with congenital fibrinogen disorders is not recommended.  239 
 240 
FXIII deficiency 241 
Factor XIII (also known as fibrin stabilising factor) contributes to clot stability by cross linking loose 242 
fibrin polymers, increasing tensile strength and reducing susceptibility to fibrinolysis (Anwar and 243 
Miloszewski, 1999). FXIII also crosslinks alpha-2-antiplasmin to fibrin which significantly decreases its 244 
susceptibility to lysis (Sakata & Aoki, 1980; Fraser et al., 2011).  Thus, in the absence of FXIII, the fibrin 245 
meshwork is unstable and susceptible to lysis by plasmin (Board et al., 1993; Mosesson et al., 2008; 246 
Chapman et al., 2016). Congenital FXIII deficiency is rare in people and only one case report exists in the 247 
veterinary literature describing FXIII deficiency in a dog (Acharya et al., 2004; Kong et al., 248 
2014). Treatment options are similar to those previously discussed for cats and dogs with haemophilia 249 
including the use of cryoprecipitate.   250 
 251 
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Breed Associated Hyperfibrinolysis: Greyhounds 252 
Delayed haemorrhage is reported following trauma and surgery in greyhounds in the absence of primary 253 
or secondary coagulation derangement (Lara-García et al., 2008). The prevalence of delayed post-254 
operative bleeding following routine gonadectomy in Greyhounds is reported to be as high as 26% (Lara-255 
García et al., 2008) although it is possible that surgeon inexperience, combined with the thin skin and 256 
haircoat of the breed, contributed to an increased incidence of haemorrhage and enhanced detection of 257 
bruising in this study. Nonetheless, the reported prevalence of haemorrhage in Greyhounds following 258 
gonadectomy is significantly higher than the prevalence of 0-2% reported in other dog breeds (Berzon, 259 
1979; Pollari et al., 1996; Burrow et al., 2005; Peeters & Kirpensteijn, 2011). Delayed haemorrhage is 260 
typically associated with the surgical site, however in some Greyhounds bleeding may progress to a 261 
generalised haemostatic disorder requiring intensive care and blood product administration (Marín et al., 262 
2012a; Marín et al., 2012b; Lara-García et al., 2008).  263 
When comparing Greyhounds who developed post-operative bleeding and those who did not, no 264 
significant difference in platelet count or function, PT, aPTT, fibrinogen, D-dimer, factor XIII and 265 
plasminogen concentration was found (Lara-García et al., 2008). However, alpha-2 antiplasmin and 266 
antithrombin levels were significantly reduced (although still within reference range) in the group of 267 
greyhounds with delayed post-operative bleeding (Lara-García et al., 2008). The absence of primary or 268 
secondary coagulation derangement combined with the delayed onset of bleeding suggest that enhanced 269 
fibrinolysis may be the primary mechanism behind post-operative bleeding in this breed (Lara-García et 270 
al., 2008). Furthermore the incidence of delayed post-operative haemorrhage is reduced in Greyhounds 271 
receiving peri-operative antifibrinolytic drugs (Marín et al., 2012).  272 
 273 
Current research using viscoelastic techniques does not strongly support the clinical suspicion of 274 
hyperfibrinolysis as the cause of delayed haemorrhage in Greyhounds (Vilar et al., 2008; Shropshire 2018). 275 
This may be due to low viscoelastic test sensitivity to detect endogenous fibrinolytic activity, and it is also 276 
possible that results may be affected by the high haematocrit in this breed (Bochsen et al., 2011; Raza et 277 
al., 2013; Brooks et al., 201). The only standard TEG variables associated with delayed haemorrhage in 278 
Greyhounds are alpha angle and maximal amplitude, both of which are influenced by fibrin cross-linking 279 
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(Vilar et al., 2008). Hyperfibrinolysis was not detected by tissue factor activated tPA TEG in healthy 280 
Greyhounds (Shropshire 2018). However, to the authors’ knowledge, kaolin and tissue factor assays or 281 
tPA TEG have not been utilised to assess coagulation and fibrinolysis in traumatised or post-surgical 282 
Greyhounds with delayed haemorrhage. 283 
 284 
Management of haemorrhage in greyhounds following trauma or surgery should initially focus on 285 
ensuring appropriate surgical haemostasis has been achieved and ruling out a primary or secondary 286 
coagulopathy. To avoid misdiagnosis and inappropriate treatment, it is important not to immediately 287 
attribute unexplained haemorrhage in this breed to hyperfibrinolysis. In Greyhounds with haemorrhage 288 
suspected to be, at least in part, secondary to hyperfibrinolysis, treatment with antifibrinolytic drugs can 289 
be considered. The prophylactic use of antifibrinolytic drugs in Greyhounds undergoing surgery should 290 
be considered based prior history and risk-benefit analysis.  291 
 292 
Acquired Hyperfibrinolysis 293 
Acquired hyperfibrinolysis in people is associated with DIC, trauma, neoplasia, end stage liver cirrhosis 294 
and obstetric complications (Tallman & Kwaan, 1992; Hyman et al., 2011; Asakura, 2014; Leebeek & 295 
Rijken, 2015; Davenport & Brohi, 2016; Hibbs et al., 2018). Acquired primary hyperfibrinolysis associated 296 
with quantitative and/or qualitative abnormalities of proteins involved in regulation of the fibrinolytic 297 
pathway has been reported in cats and dogs with haemoperitoneum, cavitary effusions, acute traumatic 298 
coagulopathy and Angiostrongylus vasorum infection (Fletcher et al., 2016; Yoo et al., 2016; Muri et al., 2018; 299 
Sigrist et al., 2017, 2018; Zoia et al., 2018, 2017). Primary hyperfibrinolysis has been diagnosed in cats 300 
with haemorrhagic pleural and peritoneal effusion and following snake envenomation (Fuchs et al., 2017; 301 
Sigrist et al., 2018). Acquired secondary hyperfibrinolysis is described in dogs with DIC due to up-302 
regulation of a normal fibrinolytic pathway (Vilar-Saavedra and Hosoya, 2011).  303 
 304 
Disseminated Intravascular Coagulation  305 
Disseminated intravascular coagulation (DIC) is an acquired consumptive thrombo-haemorrhagic 306 
disorder. It occurs when an underlying disease results in the systemic activation of coagulation and 307 
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fibrinolysis. Diseases reported to incite DIC in cats and dogs are numerous and varied; systemic infection, 308 
inflammation and neoplasia are most commonly associated with DIC in veterinary patients (Feldman et 309 
al., 1981; Estrin et al., 2006.; Wiinberg et al., 2008). The clinical manifestations of DIC are influenced by 310 
the underlying aetiology, host response and co-morbid conditions (Bick et al., 1999). Depending on the 311 
ever-changing balance between pro-thrombotic and anticoagulant, antifibrinolytic and profibrinolytic 312 
factors the phenotype may be subclinical, thrombotic or hyperfibrinolytic (Asakura, 2014; Wada et al., 313 
2014).  314 
 315 
Thrombin generation in DIC is initiated when tissue factor expression by vascular endothelial cells, 316 
monocytes or neoplastic cells activates coagulation factors (Versteeg et al., 2013). Proinflammatory 317 
cytokines and chemokines propagate coagulation, impair physiological anticoagulant pathways and 318 
suppress fibrinolysis (Simmons & Pittet, 2015, Levi & van der Poll, 2017). Consumption and depletion of 319 
anticoagulant factors further sustains the hypercoagulable state (Feldman et al., 1981; Marder & Francis, 320 
1987, Levi & Sivapalaratnam, 2018). Initially patients are hypercoagulable, however at this early stage 321 
microthrombi formation may not be clinically apparent and DIC is “non-overt” (Asakura, 2014; Wada et 322 
al., 2014). Continued formation and deposition of fibrin will eventually result in microcirculatory 323 
impairment and organ dysfunction. Furthermore, the increased utilisation and depletion of platelets 324 
ultimately results in a clinically apparent or “overt” consumptive coagulopathy (Asakura, 2014; Wada et 325 
al., 2014). This systemic activation of coagulation typically results in concurrent complementary activation 326 
of the fibrinolytic pathway.  327 
  328 
Thrombosis predominates in patients with DIC when the fibrinolytic response to systemic coagulation is 329 
inadequate or impaired. Organ dysfunction is common and haemorrhage is infrequently observed (Estrin 330 
et al., 2006; Wiinberg et al., 2008). Severe impairment of the fibrinolytic system is observed in patients 331 
with endotoxaemia or sepsis when shutdown of fibrinolysis occurs secondary to increased endothelial 332 
release of PAI-1 (Sawdey et al., 1989; Madoiwa et al., 2006; Levi et al., 2009; Wada et al., 2014). In 333 
patients with a prothrombotic DIC phenotype it is the development of a consumptive coagulopathy 334 
rather than imbalanced hyperfibrinolysis that results in clinical signs of haemorrhage. This phenotype is 335 
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also referred to as suppressed-fibrinolytic-type DIC (Asakura, 2014). Administration of antifibrinolytic 336 
agents to prothrombotic patients with impaired fibrinolysis has the potential to cause harm. As such, 337 
current treatment guidelines do not recommend the routine use of antifibrinolytic agents in people with 338 
DIC (Levi et al., 2009; Wada et al., 2014).  339 
  340 
Occasionally life-threatening haemorrhage is reported to occur in people with a hyperfibrinolytic DIC 341 
phenotype, also referred to as enhanced-fibrinolytic DIC where increased profibrinolytic factors are 342 
present (Asakura, 2014). Hyperfibrinolysis results in rapid dissolution of  microthrombi and therefore 343 
organ dysfunction due to microcirculatory impairment is uncommon (Asakura et al., 2001). Enhanced 344 
fibrinolytic DIC leading to significant haemorrhage has been associated with acute promyelocytic 345 
leukaemia, aortic aneurysm, prostatic carcinoma and amyloidosis in people (Tallman & Kwaan, 1992; 346 
Adam et al., 2004; Takahashi et al., 2008; Prokopchuk-Gauk & Brose, 2015). DIC and hyperfibrinolysis is 347 
reported in dogs with metastatic mammary carcinoma and increased circulating levels of uPA occur in 348 
dogs with metastatic disease (Mischke et al., 1998; Ramos et al., 2017). Hypocoagulation and 349 
hyperfibrinolysis have also been documented in a dog with DIC secondary to metastatic 350 
haemangiosarcoma using TF activated TEG (Vilar-Saavedra and Hosoya, 2011). Further studies are 351 
required to interrogate the role of hyperfibrinolysis induced haemorrhage in cats and dogs with DIC.  352 
  353 
Disseminated intravascular coagulation is associated with a poor prognosis in cats and dogs (Estrin et al., 354 
2006). The dynamic nature of DIC makes optimising therapeutic interventions challenging. Point of care 355 
thromboelastometry has been utilised to diagnose, guide and monitor treatment of haemorrhage in 356 
people with a hyperfibrinolytic DIC phenotype (Velez and Friedman, 2011). In the future, point of care 357 
viscoelastic techniques may provide the opportunity to interrogate the contribution of hyperfibrinolysis to 358 
haemorrhage observed in cats and dogs with DIC. Current therapy recommendations for haemorrhage 359 
associated with DIC includes blood product administration to replenish oxygen carrying capacity, 360 
platelets, coagulation factors and inhibitors (Papageorgiou et al., 2018). The introduction of 361 
antifibrinolytic agents to the therapeutic protocol of cats and dogs with documented enhanced-362 
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fibrinolytic DIC has the potential to be blood product sparing in addition to reducing morbidity and 363 
mortality.  364 
  365 
Cavitary Effusions 366 
Haemorrhagic fluid aspirated from the pericardial, pleural or peritoneal cavity will not clot and the 367 
absence of clot formation is utilised clinically to confirm that inadvertent sampling from the heart or 368 
vasculature has not occurred (Murphy & Warman, 2007). The primary mechanism behind the formation 369 
of this anti-coagulant environment relates to the fibrinolytic activity of mesothelial cells lining the 370 
pericardium, pleural space and peritoneum (Mutsaers & Wilkosz, 2007). Their fibrinolytic activity is 371 
achieved primarily through the secretion of tPA and uPA, which cleaves plasminogen found in 372 
pericardial, pleural and peritoneal fluid (Idell et al., 1992; Ivarsson et al., 1998). Mesothelial cells can 373 
further enhance anticoagulation by increasing local expression of protein C (Iakhiaev and Idell, 2006). 374 
Severe injury to the pleura and peritoneum i.e. due to surgical trauma, sepsis, ischaemia and neoplasia, 375 
activates coagulation and suppresses fibrinolysis. The formation of fibrous adhesions is a common 376 
sequelae to pleural and peritoneal disease when fibrinolysis is suppressed (Mutsaers & Wilkosz, 2007; 377 
Stommel et al., 2014).  378 
 379 
Systemic hyperfibrinolysis secondary to cavitary effusion is thought to occur due to resorption of 380 
hyperfibrinolytic fluid from the lymphatic circulation and subsequent return to the systemic circulation 381 
via the thoracic duct (Mutsaers et al., 2015). Elevated FDP and D-dimer concentrations consistent with 382 
increased fibrinolytic activity have been documented in 40% of dogs with pleural effusion and 50% with 383 
peritoneal effusion secondary to a variety of causes. In both studies primary hyperfibrinolysis due to lysis 384 
of fibrinogen was diagnosed, and increased lysis of fibrin excluded, based on discordant FDP and D-385 
dimer concentrations (Zoia et al., 2017, 2018). This method of diagnosis is problematic as the sensitivity 386 
and specificity of utilising discordant FDPs and D-dimers to diagnose primary hyperfibrinolysis is 387 
unknown and causes of discordant results other than primary hyperfibrinolysis are also possible (Sato, 388 
Takahashi and Shibata, 1995; Song et al., 1999). Thromboelastometry has been utilised to diagnose 389 
hyperfibrinolysis in dogs with spontaneous haemoperitoneum which occurred secondary to neoplasia in 390 
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96% of patients, D-dimers were also found to be increased in this group (Fletcher et al., 2016). It is likely 391 
that rupture of neoplastic lesions resulting in activation of coagulation, fibrin formation and concurrent 392 
increased fibrinolytic activity contributed to the reported increase in FDP and D-dimer concentration.  393 
 394 
Cavitary effusions occur secondary to a number of diseases such as liver failure, congestive heart failure, 395 
neoplasia, sepsis and pancreatitis, all of which have been associated with DIC (Fletcher et al., 2016; Zoia 396 
et al., 2017, 2018). Elevated FDP and D-dimer concentrations occur in patients with DIC due to 397 
concurrent activation of the fibrinolytic system (Levi et al., 2009). Administration of antifibrinolytic drugs 398 
to patients with DIC is not recommended, therefore due to the risk of misdiagnosis causing harm, 399 
discordant FDP and D-dimer concentrations should not be used to diagnose primary hyperfibrinolysis as 400 
a cause of haemorrhage in patients with cavitary effusions (Wada et al., 2014; Levi et al., 2009). 401 
Prospective studies using viscoelastic techniques are required to interrogate the extent to which primary 402 
hyperfibrinolysis contributes to haemorrhage in cats and dogs with cavitary effusions and whether this 403 
represents a novel therapeutic target.  404 
 405 
Hepatic failure 406 
The liver is an essential organ in coagulation as it is the primary source of most coagulation factors and 407 
fibrinolytic proteins, it is also responsible for their clearance (Mammen, 1992; Kavanagh et al., 2011). 408 
Coagulation changes associated with liver disease are dynamic and multifactorial, both haemorrhage and 409 
thrombosis are reported with liver disease (Mammen, 1992; Rogers et al., 2008; Kavanagh et al., 2011; 410 
Dircks et al., 2012; Respess et al., 2012; Kelley et al., 2015).  Haemorrhage can occur due to 411 
thrombocytopaenia, thrombocytopathia, decreased concentrations of procoagulant factors (factors I, II, 412 
V, VII, XIII), dysfibrinogenaemia and hypofibrinogenaemia (Willis, 1989; Dunayer & Gwaltney-Brant, 413 
2006; Botsch et al., 2009; Poldervaart et al., 2009; Prins et al., 2010). Thrombosis may occur due to 414 
decreased concentration of antithrombin and protein C, increased vWF and increased FVIII (Lisciandro 415 
et al., 1998; Kummeling et al., 2006; Toulza et al., 2006; Dereszynski et al., 2008; Prins et al., 2010). 416 
Furthermore, DIC occurs in cats and dogs with liver disease and may contribute to a consumptive 417 
coagulopathy (Lisciandro et al., 1998; Peterson et al 1998.; Prins et al., 2010).  418 
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 419 
Dysfunction of the fibrinolytic system is also reported in people and dogs with liver disease and may 420 
result in hypofibrinolysis or hyperfibrinolysis, the latter of which can produce a consumptive 421 
coagulopathy (Pernambuco et al., 1993; Kelley et al., 2015; Leebeek & Rijken, 2015). Hypocoagulation 422 
and hyperfibrinolysis is documented in people and veterinary patients with liver disease and is associated 423 
with disease severity ( Kelley et al., 2015; Fry et al., 2017). Dogs with acute liver disease trend towards 424 
hypocoagulability and hyperfibrinolysis as functional impairment occurs (Kelley et al., 2015). 425 
Hyperfibrinolysis can occur due to decreased hepatic production of anti-fibrinolytic proteins such as 426 
alpha-2-antiplasmin (Williams, 1989). Decreased hepatic clearance of plasminogen activators and plasmin 427 
also contributes to a hyperfibrinolytic state (Leebeek and Rijken, 2015). In addition, ascites is a negative 428 
prognostic indicator that is often associated with severe liver disease in cats and dogs and may result in 429 
systemic primary hyperfibrinolysis (Wright et al., 1999; Raffan et al., 2009).  430 
 431 
Whether or not hyperfibrinolysis contributes to haemorrhage in dogs and cats with liver disease and 432 
would represent a new therapeutic target has not yet been studied. As such, empiric use of antifibrinolytic 433 
agents to treat haemorrhage in patients with liver disease cannot be advised. In this group of patients, it is 434 
prudent to consider assessment of coagulation prior to surgical interventions such as feeding tube 435 
placement and liver biopsies, assessment of fibrinolysis can also be considered, particularly if unexplained 436 
haemorrhage is occurring. In cats and dogs with hepatic impairment and reduced capacity to produce 437 
coagulation factors, hyperfibrinolysis has the potential to contribute to the rapid development of a 438 
consumptive coagulopathy. Further research is needed to establish if viscoelastic techniques could help to 439 
identify hyperfibrinolysis in cats and dogs with liver disease and guide antifibrinolytic therapy, alongside 440 
coagulation factor replacement and vitamin K, in patients with active haemorrhage or planned surgical 441 
procedures.  442 
 443 
Lungworm Infection (Angiostrongylus vasorum) 444 
Angiostrongylus vasorum infection is associated with clinical signs of coagulopathy, verminous pneumonia, 445 
pulmonary hypertension, neurological deficits, polyuria and polydipsia attributed to hypercalcaemia and 446 
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gastrointestinal signs (Chapman et al., 2004; Esteves et al., 2004; Nicolle et al., 2006; Wessmann et al., 447 
2006; Traversa et al., 2008; Koch & Willesen, 2009; Helm et al., 2010) Haemorrhage in dogs with 448 
A.vasorum has been associated with von Willebrand factor deficiency, immune mediated 449 
thrombocytopaenia, consumptive coagulopathy secondary to DIC, vascular injury and more recently 450 
hyperfibrinolysis (Schelling et al., 1986; Caruso & Prestwood, 1988; Cury & Lima, 1996; Ramsey et al., 451 
1996; Gould & McInnes, 1999; Cury et al., 2002; Garosi et al., 2005; Whitley et al., 2005; Ganter & Hofer, 452 
2008; Adamantos et al., 2015;  Sigrist et al., 2017).  453 
 454 
Decreased fibrinogen concentration and hyperfibrinolysis using ROTEM has been reported in 67% of 455 
dogs with A.vasorum infection and haemorrhage (Sigrist et al., 2017). Treatment with fresh frozen plasma 456 
and tranexamic acid resulted in improvement or resolution of hypocoagulability and hyperfibrinolysis on 457 
ROTEM with all dogs treated surviving to discharge (Sigrist et al., 2017). The authors excluded DIC as a 458 
cause of hyperfibrinolysis based on the low fibrinogen concentration and fact that previous studies have 459 
reported haemorrhage in dogs with normal coagulation profiles and platelet count. More recently tPA 460 
modified TEG has been used to diagnose hyperfibrinolysis and guide successful treatment with 461 
tranexamic acid in a dog with A.vasorum infection (Cole et al., 2018).  462 
 463 
The pathophysiology of hyperfibrinolysis in patients infected by A. vasorum is incompletely understood. It 464 
is likely that adult nematodes interact with the intravascular environment to optimise survival by 465 
augmenting the host immune response and modulating haemostasis. Mechanical and biochemical trauma 466 
caused by adult A.vasorum nematodes and their metabolites may also induce tPA release from the vascular 467 
endothelium within the heart and pulmonary vasculature (Sigrist et al., 2017). It is yet to be determined 468 
whether A.vasorum directly enhances plasmin production and fibrinolysis as is reported in Dirofilaria 469 
immitis infection (González-Miguel et al., 2012; González-Miguel et al., 2013).  470 
 471 
It is important to note that hyperfibrinolysis is not the only possible cause of haemorrhage in dogs with 472 
A.vasorum (Schelling et al., 1986; Caruso & Prestwood, 1988; Cury & Lima, 1996; Ramsey et al., 1996; 473 
Gould & McInnes, 1999; Cury et al., 2002; Garosi et al., 2005; Whitley et al., 2005; Ganter & Hofer, 2008; 474 
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Adamantos et al., 2015). Hypercoagulability has also been documented in dogs with A.vasorum infection 475 
and therefore the prophylactic use of antifibrinolytic agents is not advised in dogs without clinical signs of 476 
haemorrhage (Adamantos et al., 2015). However, in dogs with haemorrhage due to A.vasorum infection 477 
the use of ROTEM and tPA TEG can be used to diagnose hypocoagulability, hyperfibrinolysis and guide 478 
therapy with fresh frozen plasma and antifibrinolytic drugs ( Sigrist et al., 2017; Cole et al., 2018). When 479 
possible viscoelastic techniques should be incorporated into assessment of coagulation status in dogs with 480 
haemorrhage due to A.vasorum. If viscoelastic techniques are not available then the use of antifibrinolytic 481 
agents could be considered alongside blood products in coagulopathic dogs diagnosed with A.vasorum and 482 
clinical signs of haemorrhage.  483 
 484 
Acute Traumatic Coagulopathy 485 
Trauma-induced coagulopathy (TIC) is a term used to describe the spectrum of coagulation changes 486 
which occur following severe injury (Hess et al., 2008). There are multiple phenotypes of trauma induced 487 
coagulopathy and the clinical manifestation is influenced primarily by thrombin production, platelet 488 
function and fibrinolysis (Moore et al., 2015; Shenkman et al., 2017). The accumulation of catecholamines 489 
and metabolites post injury, the extent of endothelial activation and the host immune response also effect 490 
the phenotype of TIC (Johansson et al., 2012; Cohen et al., 2009; Johansson et al., 2017).  491 
Early haemorrhage following trauma is a phenotype of TIC associated with the combined effects of acute 492 
traumatic coagulopathy (ATC) and resuscitation-associated coagulopathy (Cohen et al., 2013). Acute 493 
traumatic coagulopathy is an endogenous coagulopathy that occurs in the immediate minutes following 494 
trauma prior to, or independent of, resuscitation attempts (Brohi, 2003; MacLeod et al., 2003). 495 
Hypocoagulability and hyperfibrinolysis are the hallmarks of ATC, which is reported to occur in up to 496 
25% of severely traumatised people and is associated with a 4-fold increased risk of mortality and massive 497 
transfusion requirement (Brohi, 2003; MacLeod et al., 2003; Eastridge et al., 2006; Hess et al., 2008). 498 
Whether or not ATC is actually a form of DIC with an enhanced-fibrinolytic profile is fiercely contested, 499 
as the formation of thrombi and the consumptive coagulopathy which characterise DIC are not observed 500 
immediately following trauma ( Johansson et al., 2012; Palmer & Martin, 2014; Dobson et al., 2015). 501 
Resuscitation-associated coagulopathy occurs secondary to haemodilution with large fluid volumes, the 502 
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administration of colloids, massive transfusion and prolonged surgery which contribute to the 503 
development of acidaemia and hypothermia (Cohen, 2012; Fries et al., 2005; Martini et al., 2005).  504 
 505 
Three distinct fibrinolytic phenotypes are reported in people with acute traumatic coagulopathy; 506 
hyperfibrinolysis, physiological fibrinolysis and shutdown of fibrinolysis (Moore et al., 2014). 507 
Hyperfibrinolysis, as seen in ATC, occurs when trauma and hypoperfusion (shock) result in endothelial 508 
cell activation and glycocalyx dysfunction, platelet dysfunction, increased systemic tPA and activation of 509 
protein C (Cohen et al., 2012; Johansson et al., 2012; Wohlauer et al., 2012; Chapman et al., 2016;  510 
Greven et al, 2018). APC was initially thought to be the primary driver of hyperfibrinolysis in ATC 511 
through inhibition of PAI-1, however this has recently been called into question. It is now thought that 512 
massive release of tPA from the vascular endothelium following trauma is the primary mechanism behind 513 
ATC (Chapman et al., 2016). Increased circulating concentrations of tPA cause saturation of its inhibitor 514 
PAI-1 and fibrinolysis proceeds uninhibited as antifibrinolytic mechanisms are overwhelmed (Chapman 515 
et al., 2016). Fibrinolytic shutdown is reported in up to 60% of severely traumatised people and is 516 
associated with thrombosis and organ dysfunction (Moore et al., 2014). Hypercoagulability has been 517 
reported in 1 dog and cat following trauma (Gottlieb et al., 2017). The pathophysiology of fibrinolytic 518 
shutdown is incompletely understood, however increased circulating PAI-1 and inadequate tPA release in 519 
response to injury are proposed mechanisms (Chapman et al., 2016). 520 
 521 
Haemostatic derangement is reported in cats and dogs following trauma ( Mischke, 2005; Simpson et al., 522 
2009; Abelson et al., 2013; Holowaychuk et al., 2014; Yoo et al., 2016; Gottlieb et al., 2017; Muri et al., 523 
2018; Sigrist et al., 2017, 2018). However, evidence to support the existence of ATC characterised by 524 
hypocoagulation and hyperfibrinolysis is currently limited. Two separate case reports have documented 525 
hypocoagulation and hyperfibrinolysis using ROTEM and tPA challenged TEG in dogs with severe 526 
polytrauma (Yoo et al., 2016; Muri et al., 2018). Both dogs received antifibrinolytic drugs which resulted 527 
in the resolution of hyperfibrinolysis on ROTEM/TEG and haemorrhage control. Hyperfibrinolysis has 528 
also recently been documented in cats following trauma (Sigrist et al., 2018). ATC is likely to be 529 
challenging to diagnose in veterinary patients due to the fact that it is a dynamic coagulopathy. There is 530 
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typically a delay between the traumatic episode and presentation to centres where fibrinolysis can be 531 
assessed (generally referral hospitals). It is possible that by the time fibrinolysis can be assessed the 532 
hyperfibrinolytic phase has resolved or that the most severely traumatised animals may have succumbed 533 
to their injuries.   534 
 535 
There is great interest in the use of tranexamic acid in veterinary trauma patients due to the results of the 536 
human CRASH-2 and MATTER trials (Morrison et al., 2012; Roberts et al., 2013). These landmark trials 537 
found that empiric administration of tranexamic acid to trauma patients with haemorrhagic shock was 538 
associated with increased survival. However, CRASH-2 also reported that mortality was increased in a 539 
subset of patients when tranexamic acid was administered empirically 3-8hrs post trauma. Major 540 
haemorrhage protocols used by human trauma centres advocate restrictive crystalloid administration, 541 
empiric use of tranexamic acid within the first 3hrs post trauma and resuscitation using a 1:1:1 ratio of 542 
fresh frozen plasma, packed red blood cells and platelets (Holcomb et al., 2015).  543 
 544 
Empiric use of antifibrinolytic drugs has the potential to cause harm in hypercoagulable traumatised cats 545 
and dogs with shutdown of fibrinolysis. Viscoelastic techniques can be utilised to diagnose ATC and 546 
guide therapy in traumatised animals, however given the dynamic nature of TIC and ATC point of care 547 
assessment is advised (Holowaychuk et al., 2014; Yoo et al., 2016; Muri et al., 2018;). The coagulation 548 
status of the patient may change rapidly and increased lag time between sampling and interpretation of 549 
results could result in misdiagnosis and inappropriate treatment. Further studies are needed, however the 550 
use of antifibrinolytic drugs in traumatised cats and dogs who are bleeding and have laboratory evidence 551 
of hyperfibrinolysis is unlikely to cause harm and may be of benefit (Yoo et al., 2016; Muri et al., 2018). 552 
Furthermore, implementing balanced resuscitation using blood products, restricting crystalloid 553 
administration and performing damage control surgery in line with current recommendations in human 554 
medicine should be considered (Rossaint et al., 2016).  555 
 556 
Treatment of Hyperfibrinolytic disorders 557 
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Antifibrinolytic agents are frequently used in people to treat severe haemorrhage associated with 558 
congenital and acquired disorders of coagulation, menorrhoea, post-partum haemorrhage, neoplasia, 559 
gastrointestinal and urogenital haemorrhage, surgical haemorrhage and trauma (Mannucci, 1998). The 560 
antifibrinolytic agents most commonly used in human and veterinary medicine are Epsilon-aminocaproic 561 
acid (EACA) and tranexamic acid (TXA). Aprotinin administration is described in the human literature 562 
but was removed from the global market in 2008 due to safety concerns. In veterinary medicine the 563 
Chinese herb Yunnan Baiyao has also been anecdotally used for haemostasis, however robust evidence 564 
does not currently support its efficacy (Egger et al., 2016; Frederick et al., 2017; Lee et al., 2017).  565 
 566 
Tranexamic acid and aminocaproic acid are lysine analogues, they exert their mechanism of action by 567 
competitively binding C-terminal lysine sites on plasminogen. As a result of lysine analogue binding 568 
plasminogen is prevented from binding fibrin and plasmin formation is inhibited (Figure 3). 569 
 570 
The recommended dose of EACA for dogs with active haemorrhage is a loading dose of 50-100mg/kg 571 
IV followed by 15mg/kg administered q8hrs until haemorrhage has resolved (Hopper, 2006). In dogs 572 
100mg/kg is associated with increased clot strength in comparison to lower dosages with no adverse 573 
effects reported (Brown et al., 2016). Rapid administration may cause hypotension and gastrointestinal 574 
signs, weakness, myonecrosis, myoglobinuria and rhabdomyolysis are dose dependent adverse reactions 575 
reported in human patients following EACA administration (Borchers, 2014). To the authors’ knowledge 576 
there is no literature available regarding the use of EACA in cats.  577 
  578 
Tranexamic acid is up to 10 times more potent than EACA and its antifibrinolytic activity is superior and 579 
more sustained (Verstraete, 1985; McCormack, 2012). There is no consensus regarding optimal dosing, 580 
currently the recommended dose of TXA for dogs with active haemorrhage is 15mg/kg slow IV 581 
administered q8hrs until haemorrhage has resolved (Hopper, 2006; Osekavage et al 2018). Tranexamic 582 
acid is associated with few adverse events, although vomiting has been reported in dogs and seems to be 583 
associated with higher doses (20 mg/kg IV) or rapid bolus administration (Kelmer et al., 2013; Kakiuchi 584 
et al., 2014; Kelmer et al., 2015). It should therefore be used with caution in patients with 585 
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contraindications for vomiting, such as raised intra-ocular or intra-cranial pressure and obtunded patients 586 
vulnerable to aspiration. Tranexamic acid has been associated with seizure activity in people secondary to 587 
inhibition of gamma-aminobutyric acid type A receptors and glycine receptors, both of which are major 588 
inhibitory neurotransmitters (Lin and Xiaoyi, 2016). Evidence to guide the use of tranexamic acid in cats 589 
is currently not available.  590 
 591 
In people the incidence of thromboembolism associated with administration of antifibrinolytic agents is 592 
reported to be low (Ker et al., 2015; Nicolau-Raducu et al., 2016, Juhl et al., 2018) but this has not been 593 
established in cats and dogs.  Empiric use of these drugs is therefore not recommended in patients with 594 
pro-thrombotic conditions. Caution is also advised in the use of antifibrinolytic agents in cats and dogs 595 
with renal haemorrhage due to the risk of clot formation causing intra-renal and ureteric obstruction 596 
(Stark, 1965; Vujkovac & Sabovic, 2006). Both TXA and EACA are primarily excreted by the kidneys and 597 
in people with renal impairment TXA administration is associated with seizures (Montes et al., 2012). 598 
Although guidelines do not exist for TXA and EACA use in veterinary patients with renal impairment a 599 
reduction in dose in line with human medical recommendations is advised (Andersson et al., 1978; Jerath 600 
et al., 2018).  601 
Summary 602 
Hyperfibrinolysis occurs in both cats and dogs secondary to a variety of congenital and acquired 603 
disorders. It has been described in cats and dogs with conditions commonly encountered in primary care 604 
practice such as trauma, cavitary effusions, liver disease and A.vasorum. In addition, delayed haemorrhage 605 
attributed to hyperfibrinolysis is reported in Greyhounds following trauma and routine surgical 606 
procedures. Clinically significant haemorrhage can occur as the consequence of hyperfibrinolysis and has 607 
the potential to increase morbidity and mortality. Viscoelastic techniques provide a global assessment of 608 
coagulation and are considered superior for assessing the fibrinolytic systemic. Currently assessment of 609 
fibrinolysis using viscoelastic techniques is limited to specialist hospitals or laboratories with ROTEM and 610 
TEG, however this is changing with the recent development of point of care viscoelastic analysers. In the 611 
future it is likely that consideration and interrogation of the fibrinolytic system will become routine in the 612 
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management of coagulopathic cats and dogs in primary care practice. The authors hope that lives will be 613 
saved as our ability to recognise, diagnose and treat haemorrhage due to hyperfibrinolysis improves. 614 
 615 
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Index 1194 
Figure 1. The Fibrinolytic System 1195 
 1196 
The fibrinolytic system is activated concurrently with coagulation following vascular injury. Tissue 1197 
plasminogen activator (tPA) released from vascular endothelial cells binds and activates plasminogen to 1198 
plasmin. Following activation of plasminogen the tPA/plasmin complex binds lysine residues on fibrin. Plasmin 1199 
cleaves fibrin resulting in the formation of fibrin degradation products/D-dimers. The fibrinolytic system is 1200 
regulated and inhibited primarily by plasminogen activator inhibitor-1 (PAI-1), alpha-2-antiplasmin and 1201 
thrombin activatable fibrinolysis inhibitor (TAFI). PAI-1 is the main inhibitor of tPA and uPA and 1202 
therefore the most significant inhibitor of fibrinolysis. Alpha-2 antiplasmin inhibits fibrinolysis by 1203 
forming a complex with active plasmin to neutralise its action and also by preventing absorption of 1204 
plasminogen onto the fibrin clot. TAFIa is a potent down-regulator of fibrinolysis; by removing carboxyl-1205 
terminal lysine groups from fibrin strands it prevents the binding of plasminogen and tPA to the 1206 
thrombus.  1207 
 1208 
  1209 
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Figure 2. TEG tracing with enhanced fibrinolysis following the addition of tPA (50 IU/ml) to citrated 1210 
whole blood from a critically ill Greyhound. 1211 
 1212 




Modified TEG tracing with evidence of fibrinolysis following addition of tPA (50IU/ml) 1217 
  1218 
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Figure 3. a) Plasminogen is activated to plasmin by uPA or tPA on the surface of fibrin, resulting in 1219 
fibrinolysis and the production of fibrin degradation products. (b) Anti‐fibrinolytic drugs bind to 1220 
plasminogen C‐terminal lysine sites and inhibit activation of plasminogen to plasmin on the surface 1221 
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